Compare · OUST vs TMO
OUST vs TMO
Side-by-side comparison of Ouster Inc. (OUST) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OUST and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $257.53B, about 496.9x OUST ($518.2M).
- TMO has been more active in the news (6 items in the past 4 weeks vs 4 for OUST).
- TMO has more recent analyst coverage (25 ratings vs 18 for OUST).
- Company
- Ouster Inc.
- Thermo Fisher Scientific Inc
- Price
- $28.41-9.32%
- $690.13-0.92%
- Market cap
- $518.2M
- $257.53B
- 1M return
- -
- +4.77%
- 1Y return
- -
- +26.83%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 6
- Recent ratings
- 18
- 25
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest OUST
- Ouster Announces Date for Third Quarter 2026 Earnings Call
- SEC Form 4 filed by Ouster Inc.
- AVerMedia and Stereolabs Accelerate AI Vision Deployment with NVIDIA JetPack 7.2
- Ouster Partners with Seneca to Advance Autonomous Drone Technology for Wildfire Response Operations
- General Counsel and Secretary Chung Megan sold $389,993 worth of shares (11,484 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 189,291 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Spencer Darien sold $434,953 worth of shares (12,808 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 286,998 units (SEC Form 4) to satisfy withholding obligation
- President and CEO Pacala Charles Angus sold $1,031,847 worth of shares (30,385 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,041,816 units (SEC Form 4) (withholding tax)
- Chief Revenue Officer Jacquemet Cyrille sold $302,093 worth of shares (8,896 units at $33.96), decreasing direct ownership by 8% to 105,538 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Gianella Kenneth P. sold $532,682 worth of shares (15,686 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 245,328 units (SEC Form 4) (withholding obligation)
- Chief Technology Officer Frichtl Mark sold $637,691 worth of shares (18,778 units at $33.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 318,987 units (SEC Form 4) to satisfy tax liability
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)